Syngene International Ltd's Q4FY25 Quarter Results
- 4d ago
Result Summary
- Syngene International Ltd reported a 3.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 8.3%.
- Its expenses for the quarter were down by 7.3% QoQ and 7.9% YoY.
- The net profit increased 43.9% QoQ and increased 5.5% YoY.
- The earnings per share (EPS) of Syngene International Ltd stood at 4.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 933.00 | 962.00 | 1017.20 | -3.0% | -8.3% |
Total Expenses | 724.00 | 781.20 | 786.30 | -7.3% | -7.9% |
Profit Before Tax | 209.00 | 180.80 | 230.90 | 15.6% | -9.5% |
Tax | 20.40 | 49.70 | 52.20 | -59.0% | -60.9% |
Profit After Tax | 188.60 | 131.10 | 178.70 | 43.9% | 5.5% |
Earnings Per Share | 4.70 | 3.30 | 4.40 | 42.4% | 6.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Syngene International Ltd, a prominent player in the biotechnology and pharmaceutical industry, is known for its comprehensive contract research and manufacturing services. The company primarily engages in providing integrated services to global pharmaceutical, biotechnology, and agrochemical companies. Syngene's offerings encompass early-stage drug discovery, development, and manufacturing services. Its operations are supported by a robust infrastructure and a strong scientific workforce. While recent major developments in the company are not specified in the provided data, Syngene continues to be recognized for its strategic collaborations and expansion in research capabilities.
Revenue
In the fourth quarter of fiscal year 2025, Syngene International Ltd reported a total income of ₹933.00 crores. This represents a decrease from the ₹962.00 crores recorded in the previous quarter, reflecting a quarter-over-quarter (QoQ) decline of 3.0%. When compared to the corresponding quarter of the previous fiscal year, where the total income was ₹1017.20 crores, there is a year-over-year (YoY) decline of 8.3%. These figures illustrate the dynamic nature of revenue generation within the biotechnology and pharmaceutical sectors, where fluctuations are common due to various operational and market factors.
Profitability
Syngene's profitability metrics for Q4FY25 highlight a profit before tax of ₹209.00 crores, which marks a 15.6% increase from the previous quarter's figure of ₹180.80 crores. However, this is a decline when compared to the ₹230.90 crores recorded in the same quarter of the previous year, reflecting a YoY decrease of 9.5%. The profit after tax for Q4FY25 is ₹188.60 crores, significantly higher than the previous quarter's ₹131.10 crores, translating to a QoQ increase of 43.9%. Compared to Q4FY24, where the profit after tax was ₹178.70 crores, there is a modest YoY growth of 5.5%. The earnings per share (EPS) for the quarter is ₹4.70, which has risen from ₹3.30 in Q3FY25, indicating a QoQ increase of 42.4%, and a YoY increase from ₹4.40, reflecting a 6.8% growth.
Operating Metrics
The operating expenses for Q4FY25 were reported at ₹724.00 crores, showing a reduction from ₹781.20 crores in the previous quarter, leading to a QoQ decrease of 7.3%. Compared to the same period last fiscal year, when total expenses were ₹786.30 crores, this represents a YoY decline of 7.9%. The tax expense for the quarter stood at ₹20.40 crores, significantly lower than the ₹49.70 crores in Q3FY25, resulting in a QoQ decrease of 59.0%. When compared to the Q4FY24 tax amount of ₹52.20 crores, there is a notable YoY reduction of 60.9%. These figures reflect the company's operational efficiency and tax management within the given period, highlighting significant changes in expenses and tax outlays.
